From The Motley Fool · Prosper Junior Bakiny · · 1m 10s
TL;DR: Revolution Medicines Drug Targets 'Undruggable' Cancer
Revolution Medicines' Rasonque, the first drug to target RAS-addicted cancers, generated $198 million in five weeks.
Revolution Medicines' Rasonque achieved the strongest oncology drug launch in history with $198 million revenue in five weeks. Revolution Medicines' Rasonque, the first drug to target RAS-addicted cancers, generated $198 million in five weeks. Revolution Medicines earned approval for Rasonque, a medicine for pancreatic cancer targeting RAS-addicted cancers. Rasonque generated $198 million in five weeks, marking the strongest oncology drug launch on record.
- Rasonque Approval
- Strong Launch
- Clinical Results
- RAS-Addicted Cancers
Read the story version — the same reporting as a swipeable deck of 7 cards.






